Dose 3

BEHAVIORAL4 trials

Sponsors

Loyola University, Pennington Biomedical Research Center, University of Utah, Etern Therapeutics Wuxi Limited

Conditions

Diabetes PreventionMelanomaSafety IssuesTobacco ChewingTobacco DependenceTobacco SmokingTobacco UseTobacco Use Cessation

Phase 1

Transfer of Genetically Engineered Lymphocytes in Melanoma Patients

Active, not recruitingNCT01586403

Loyola UniversityMelanoma

Start: 2012-07-31End: 2028-09-30Updated: 2020-10-30

Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.)

CompletedNCT02088203

Pennington Biomedical Research CenterDiabetes Prevention

Start: 2014-02-28End: 2018-05-31Updated: 2019-03-21

Safety, Tolerability and Pharmacokinetics of ETD-001 Gel

Enrolling by invitationNCT07674862

Etern Therapeutics Wuxi LimitedSafety Issues

Start: 2026-03-16End: 2026-07-01Target: 56Updated: 2026-06-30

Unknown Phase

Reach Through Equitable Implementation in Utah

RecruitingNCT06881069

University of UtahTobacco Chewing, Tobacco Dependence, Tobacco Smoking +2

Start: 2025-02-13End: 2028-01-30Target: 1560Updated: 2025-03-18

Related Papers

Recent Advancements in Cell-Based Therapies in Melanoma.

2024-09-124 citations

Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.

2017-10-2040 citations

Utilizing IL-7 to generate melanoma antigen T cell receptor-modified cells for adoptive transfer in the absence of activation.

Journal of Clinical Oncology2017-05-20

T-cell therapy in metastatic melanoma: TIL 1383I TCR transduced T cells after infusion and activity in vivo.

Journal of Clinical Oncology2015-05-201 citations